These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29535127)

  • 1.
    Murcia O; Jover R; Egoavil C; Perez-Carbonell L; Juárez M; Hernández-Illán E; Rojas E; Alenda C; Balaguer F; Andreu M; Llor X; Castells A; Boland CR; Goel A
    Clin Cancer Res; 2018 Jun; 24(12):2820-2827. PubMed ID: 29535127
    [No Abstract]   [Full Text] [Related]  

  • 2. TFAP2E-DKK4 and chemoresistance in colorectal cancer.
    Ebert MP; Tänzer M; Balluff B; Burgermeister E; Kretzschmar AK; Hughes DJ; Tetzner R; Lofton-Day C; Rosenberg R; Reinacher-Schick AC; Schulmann K; Tannapfel A; Hofheinz R; Röcken C; Keller G; Langer R; Specht K; Porschen R; Stöhlmacher-Williams J; Schuster T; Ströbel P; Schmid RM
    N Engl J Med; 2012 Jan; 366(1):44-53. PubMed ID: 22216841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer.
    Park SJ; Kim SM; Hong YS; Lee JL; Kim JE; Kim KP; Hong SM; Jin DH; Kim CW; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC; Kim TW
    Oncology; 2015; 88(2):122-32. PubMed ID: 25341849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
    Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
    Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer.
    Sun J; Du N; Li J; Zhou J; Tao G; Sun S; He J
    Technol Cancer Res Treat; 2016 Apr; 15(2):285-95. PubMed ID: 25810491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer.
    Zhang ZM; Wang Y; Huang R; Liu YP; Li X; Hu FL; Zhu L; Wang F; Cui BB; Dong XS; Zhao YS
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2119-27. PubMed ID: 24996990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
    Moutinho C; Martinez-Cardús A; Santos C; Navarro-Pérez V; Martínez-Balibrea E; Musulen E; Carmona FJ; Sartore-Bianchi A; Cassingena A; Siena S; Elez E; Tabernero J; Salazar R; Abad A; Esteller M
    J Natl Cancer Inst; 2014 Jan; 106(1):djt322. PubMed ID: 24273214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
    Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
    PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
    Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
    Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TFAP2E methylation promotes 5‑fluorouracil resistance via exosomal miR‑106a‑5p and miR‑421 in gastric cancer MGC‑803 cells.
    Jingyue S; Xiao W; Juanmin Z; Wei L; Daoming L; Hong X
    Mol Med Rep; 2019 Jul; 20(1):323-331. PubMed ID: 31115533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma.
    Kunicka T; Prochazka P; Krus I; Bendova P; Protivova M; Susova S; Hlavac V; Liska V; Novak P; Schneiderova M; Pitule P; Bruha J; Vycital O; Vodicka P; Soucek P
    BMC Cancer; 2016 Oct; 16(1):795. PubMed ID: 27733154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
    Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
    Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
    Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
    Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
    Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
    Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
    Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.